CLINICAL SIGNIFICANCE OF ANTI-RO52/TRIM21 ANTIBODIES IN SYSTEMIC AUTOIMMUNE RHEUMATIC DISORDERS: PRELIMINARY RESULTS

Autor:	Cristina Pomirleanu, Codrina Ancuta, Iasi Pharmacy, R. Paiu, G. Strugariu, L. Petrariu
Rok vydání:	2017
Předmět:	systemic autoimmune rheumatic disorders biology business.industry anti-ro52/trim21 antibodies RC581-607 Immunology biology.protein Medicine General Materials Science Clinical significance Immunologic diseases. Allergy Antibody business
Zdroj:	Romanian Journal of Rheumatology, Vol 26, Iss 3, Pp 129-134 (2017)
ISSN:	2069-6086 1843-0791
DOI:	10.37897/rjr.2017.3.4
Popis:	Although antibodies targeting Ro52 protein/TRIM21 are commonly detected in systemic autoimmune rheumatic disorders (SARDs), their clinical significance and pathobiologic role remains incompletely understood. Objectives. We aimed to define clinical relevance and immunological associations of anti-Ro52/TRIM21 positivity in a cohort of patients with SARDs. Methods. We retrospectively reviewed medical records of 97 consecutive SARDs who attended at least once our Rheumatology Department between March 2016 and June 2017. Clinical manifestations, rheumatoid factor (RF) (Latex and Waalter-Rose tests), antinuclear antibodies (ANA>1:100, immunofluorescence assays) as well as detailed ANA profile (nRNP/Sm, Sm, SS-A/Ro, Ro52/TRIM21, SS-B/La, Scl-70, PM/Scl, Jo-1, CENP-B, PCNA, dsDNA, nucleosome, histone, P-ribosomal protein, AMA-M2, DFS70) (line immunoblot assay) were systematically evaluated. Statistical analysis was performed in SPSS19.0, assuming significance for p
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b3bb440ffd6f75c2222b5dfd952be39b https://doi.org/10.37897/rjr.2017.3.4 Zobrazit plný text záznamu Plný text ve formátu PDF